Earnings summaries and quarterly performance for Sionna Therapeutics.
Executive leadership at Sionna Therapeutics.
Board of directors at Sionna Therapeutics.
Bruce Booth
Detailed
Director
H. Edward Fleming, Jr.
Detailed
Director
Joanne Viney
Detailed
Director
Joshua Resnick
Detailed
Director
Laurie Stelzer
Detailed
Director
Lucian Iancovici
Detailed
Director
Marcella Kuhlmann Ruddy
Detailed
Director
Paul Clancy
Detailed
Chairperson of the Board
Peter A. Thompson
Detailed
Director
Research analysts covering Sionna Therapeutics.
Recent press releases and 8-K filings for SION.
Sionna Provides Update on Cystic Fibrosis Pipeline and Financial Position
SION
New Projects/Investments
Guidance Update
- Sionna is focused on transforming the standard of care in cystic fibrosis (CF) by targeting NBD1, with two primary compounds in development: SION-719 for an add-on strategy to Trikafta, and SION-451 as the anchor for a prioritized dual combination strategy.
- The company anticipates Phase 2a proof-of-concept data for SION-719 and data for the dual combination strategy with SION-451 in mid-2026.
- Sionna completed an IPO in February, raising $219 million, which provides a cash runway into 2028 and financial flexibility to execute its strategy.
- For SION-719, the company aims for at least a 10 millimole per liter change in sweat chloride, which is considered clinically meaningful and is projected to equate to approximately 3 points of FEV1.
- Sionna in-licensed three clinical-stage compounds from AbbVie, including galicaftor (2222), to expand its complementary mechanism strategy for dual combinations, with 2222 currently being evaluated in a Phase 1 healthy volunteer study in combination with 451.
Dec 4, 2025, 2:45 PM
Sionna Provides Update on Cystic Fibrosis Pipeline and Financial Position
SION
New Projects/Investments
Guidance Update
- Sionna is advancing two lead NBD1 stabilizer candidates for cystic fibrosis: SION-719 in a Phase 2a proof-of-concept study as an add-on to Trikafta, and SION-451 as the anchor for a prioritized dual combination strategy, with key data readouts for both programs expected in mid-2026.
- Following its February 2025 IPO that raised $219 million, Sionna has a cash runway into 2028, providing financial flexibility to execute its strategy and pursue its goal of achieving at least a 10 millimole per liter change in sweat chloride with SION-719.
- The company targets the $12 billion cystic fibrosis market, projected to grow to $15 billion, aiming to offer new, more effective options for patients.
Dec 4, 2025, 2:45 PM
Sionna Therapeutics reviews 2025 achievements and outlines 2026 clinical milestones
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics completed Phase 1 programs for its NBD1 stabilizers, SION-719 and SION-451, in 2025, reporting positive data for both compounds.
- The company initiated a Phase 2 proof-of-concept study for SION-719 as an add-on to Trikafta and a healthy volunteer Phase 1 study for SION-451 in a dual combination with other modulators, with data for both studies anticipated in mid-2026.
- Sionna completed an IPO in February 2025, raising over $219 million in gross proceeds, which provides a cash runway into 2028.
- The company's strategy focuses on improving CFTR function and normalizing sweat chloride levels, with a preferred dual combination approach, believing their NBD1 mechanism offers differentiated efficacy compared to existing treatments.
Dec 3, 2025, 5:30 PM
Sionna Therapeutics reviews 2025 accomplishments and outlines 2026 clinical milestones
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics completed Phase 1 programs for its two NBD1 stabilizers, SION-719 and SION-451, in 2025, reporting positive data.
- The company initiated a Phase 2 proof-of-concept study for SION-719 as an add-on to Trikafta and a healthy volunteer Phase 1 study for SION-451 in a dual combination, with data from both expected in mid-2026.
- Sionna completed an IPO in February 2025, raising over $219 million in gross proceeds, which provides a cash runway into 2028.
- The company aims to address the unmet need in cystic fibrosis by driving more patients to normal CFTR function, noting that two-thirds of patients on current standard-of-care treatments do not achieve normal levels.
- Sionna expresses high confidence in its CFHBE assay, which has been validated by matching results with published clinical data for Vertex compounds, supporting its differentiated NBD1 mechanism.
Dec 3, 2025, 5:30 PM
Sionna Therapeutics Highlights 2025 Accomplishments and 2026 Clinical Milestones
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics completed Phase I programs for its two NBD1 stabilizers, SION-719 and SION-451, in 2025 with positive data.
- The company initiated a Phase II proof-of-concept study for SION-719 (Precision CF study) and a healthy volunteer Phase I study for SION-451 in combination with other modulators, with data for both expected in mid-2026.
- Sionna completed an IPO in February 2025, raising over $219 million gross proceeds, which provides a cash runway into 2028.
- The company's strategy involves advancing SION-719 as an add-on to Trikafta and SION-451 as the anchor for a preferred dual combination approach, aiming to improve CFTR function and normalize sweat chloride levels, with the SION-719 Phase II study powered for at least a 10 mmol/L change in sweat chloride.
Dec 3, 2025, 5:30 PM
Sionna Provides Updates on Cystic Fibrosis Programs and Cash Runway
SION
New Projects/Investments
Guidance Update
- Sionna is advancing two NBD1 stabilizers for cystic fibrosis: 719 is in a Phase 2a proof-of-concept study (PreciSION CF study) with data expected by mid-2026.
- A healthy volunteer dual combination study for 451 with two different correctors (Sion-2222 and Sion-109) has also started, with data anticipated by mid-2026.
- The company targets at least a 10-millimole sweat chloride reduction in the Phase 2a study, a clinically meaningful bar that could translate to three percentage points of FEV1 improvement.
- Sionna reported $325 million in cash at the start of Q3, extending its cash runway into 2028, well past the mid-2026 data readouts.
Nov 12, 2025, 1:00 PM
Sionna Therapeutics Provides Clinical Development and Financial Updates
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics is developing two NBD1 stabilizers, 719 and 451, for cystic fibrosis, aiming to transform the standard of care.
- The Phase 2a PreciSION CF study for 719, an add-on to Trikafta, is targeting at least a 10-millimole sweat chloride reduction, with data expected in mid-2026.
- A healthy volunteer dual combination study for 451 with either Sion-2222 or Sion-109 is also underway, with data anticipated by mid-2026.
- Sionna reported a cash balance of $325 million at the start of Q3, providing a cash runway into 2028, extending beyond the mid-2026 data readouts.
Nov 12, 2025, 1:00 PM
Sionna Therapeutics Provides Clinical Development and Financial Updates
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics is advancing two NBD1 stabilizers for cystic fibrosis, aiming to transform the standard of care.
- The 719 compound has progressed to a Phase IIa proof of concept study (PreciSION CF), targeting at least a 10-millimole sweat chloride reduction, with data expected by mid-2026.
- A healthy volunteer dual combination study for 451 with either Sion-2222 or Sion-109 is also in progress, with data anticipated by mid-2026.
- The company reported $325 million in cash at the end of Q3, providing a cash runway into 2028.
Nov 12, 2025, 1:00 PM
Sionna Provides Update on Clinical Programs and Financial Position
SION
New Projects/Investments
Guidance Update
- Sionna (SION) completed its IPO in February 2025 and is focused on developing NBD1 stabilizers to treat Cystic Fibrosis, aiming to capture a share of the $11 billion market currently dominated by Vertex.
- The company has two ongoing clinical studies with key data readouts anticipated in mid-2026: a Phase 2A proof-of-concept study for its NBD1 stabilizer 719 as an add-on to Trikafta in CF patients, and a healthy volunteer dual combination study for its NBD1 stabilizer 451.
- The Phase 2A study for 719 is designed to demonstrate a 10 millimole per liter change in sweat chloride, which is considered a clinically meaningful benefit.
- Sionna reported $325 million in cash at the end of Q3, providing a cash runway into 2028, which extends beyond the anticipated mid-2026 clinical trial readouts.
Nov 11, 2025, 1:30 PM
Sionna Therapeutics Reports Third Quarter 2025 Financial Results and Pipeline Progress
SION
Earnings
New Projects/Investments
Management Change
- Sionna Therapeutics reported a net loss of $20.3 million for the third quarter of 2025, compared to a net loss of $25.4 million for the third quarter of 2024.
- The company held $325.0 million in cash and cash equivalents as of September 30, 2025, which is projected to fund operations into 2028.
- Key pipeline advancements include the initiation of the PreciSION CF Phase 2a trial for SION-719 and a Phase 1 trial for SION-451 in dual combinations, with topline data expected in mid-2026.
- Research and development expenses were $16.0 million for Q3 2025, down from $24.6 million in Q3 2024, while general and administrative expenses increased to $7.8 million from $3.4 million.
Nov 5, 2025, 12:14 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more